We have previously reported that ovarian cancer G protein-coupled receptor 1 (OGR1) is a new metastasis suppressor gene. Although, we have reported the expression of a new intronless gene for casein kinase 2α (CSNK2A3) in human cells, there is no previous report on regulation of CK2α expression in cancer cells. In this study, we found that OGR1 up-regulates expression of CSNK2A3 by about 3 folds in A549 cells but not CSNK2A1. OGR1 also up-regulates expression of neutral endopeptidase (NEP). The OGR1 induced inhibition of A549 cell migration is completely abrogated by inhibition of casein kinase 2α activity, whereas partial abrogation (~ 30%) was observed in the presence of NEP inhibition. The results also revealed that OGR1 regulates CSNK2A3 via activation of Rac1/cdc42 and MAPKs pathways. CK2 is ubiquitously expressed and in contrast it is believed to be a constitutively active enzyme and its regulation appears to be independent of known second messengers. Our findings also suggest that the aberrantly casein kinase 2α expression found in various cancer cells may the due to CSNK2A3 expression which is potentially regulated by several master regulators of the developmental pathways rather than well-known casein kinase 2α gene, CSNK2A1.
Introduction
The ovarian cancer G protein-coupled receptor 1 (OGR1) and related subfamily members mediate the functions of several lysophospholipids which include endothelial barrier function, endothelial cell proliferation, migration, and tube formation, T cell migration, glucocorticoid-induced thymocyte apoptosis, and globoid cell formation [1] [2] [3] [4] [5] . OGR1 gene has been shown to be expressed at lower levels in metastatic compared with primary prostate cancer tissues [6] . Recently, we have shown using an orthotopic mouse metastasis model that OGR1 is a novel metastasis suppressor gene for prostate cancer when it is re-expressed in cancer cells [5] . Further, other researchers have also reported that OGR1 inhibits breast and ovarian cancer cells in vitro when it is re-expressed in cancer cells [7, 8] .
However, our previous study revealed that OGR1 has inhibitory effect on prostate cancer tumorigenesis when expressed in host/stromal cells using OGR1 knockout TRAMP mice prostate cancer model [9] . Further, we have also demonstrated that OGR1 significantly inhibited melanoma tumorigenesis in OGR1 knockout mice [10] . Another study of Horman SR, et al. has reported that murine colon tumor implants in OGR1 knockout mice displayed delayed tumor growth [11] . Therefore, these previous reports clearly indicate that in contrast to OGR1's tumor-suppressing role in tumor cells, host cell OGR1 may be involved in and/or required for tumor growth. OGR1 and its subfamily G protein-coupled receptors (GPCRs), GPR4, G2A and T-cell death-associated gene 8 (TDAG8), have been shown to have proton-sensing ability [12, 13] . Many of these proton sensing activities have been identified in cells over-expressing one or more of these GPCRs. More recently, proton sensing activities have been detected in cells from GPR4-and TDAG8-, but not G2A-deficient mice [3, 14, 15] .
Previous studies have reported that OGR1 activity on tumorigenesis is independent of its pH-sensing activities. These G-protein coupled receptors also appear to have ligand-independent constitutive activity [5, 7, 8, 10] . However, the signalling pathway of OGR1 in inhibition of metastasis is not clearly understood. One previous report has revealed that OGR1 induced activation of Rho but downregulation of Rac1 in breast cancer cell line [8] . Therefore, it is important to investigate the downstream cellular proteins of OGR1 in its function as metastasis suppressor gene.
[3]
expression is very limited. The original view in the literature is that CK2 is predominantly regulated post-transcriptionally; however, recent studies strongly suggest that regulation at the transcriptional level is also important in some cancers [33] . Recently, Das, N et al have reported that ERα transcriptionally activates CKα [34] . Unpredictably, some cancers show under-expression of CK2 transcripts in breast, ovarian, and pancreatic cancer [33] . Furthermore, CK2 transcript levels could have a prognostic value in cancers (e.g. CK2α in squamous cell carcinoma of the lung). For the most part, high levels of CK2 transcript correlate with lower overall survival (e.g. breast and ovarian cancer, glioblastoma, kidney and liver cancer) [33, [35] [36] [37] . However, in lung adenocarcinoma, high levels of CSNK2A2 (CK2α′) and CSNK2A3 correlate with higher survival rates [24, 33] . Similar to lung adenocarcinoma, overexpression of CSNK2A3 in renal clear cell carcinoma led to increased survival [24] . From the above data, it is not clear whether CK2 is anti-cancer or pro-cancer molecule.
Neutral endopeptidase 24.11 (NEP, neprilysin, enkephalinase, CD 10) is a widely distributed membrane enzyme, occurring on a variety of cells [38] . The biological and regulatory effects of NEP are presumed only to result from its enzymatic function [39, 40] . However, recent data suggest that NEP protein expression in of itself can effect signal transduction pathways that regulate cell growth [41, 42] and apoptosis [43] . Tokuhara et al reported tumors with high NEP and low CD13 were associated with better prognoses [44] . Gurel et al reported that in lung squamous cell carcinomas both tumoral and stromal NEP expression were unfavorable prognostic factors, while in non-squamous cell carcinomas tumoral NEP expression was a favorable prognostic factor [45] . In a study conducted by Kristiansen et al, tumoral NEP expression was not associated with prognosis in NSCLCs [46] . Ono et al reported that neither tumoral nor stromal NEP expression correlated with prognosis in stage I lung squamous cell carcinomas [47] . Recently, Leithner et al reported that high NEP expression, based on gene expression analysis, was associated with unfavorable prognoses in lung adenocarcinomas but not in non-adenocarcinomas [48] . However, it is unclear whether this result was based on tumoral or stromal NEP expression because localization of NEP was not confirmed via immunohistochemistry. Therefore, the prognostic value of tumoral NEP for early-stage lung adenocarcinoma remains unknown. NEP expression was lower in certain carcinomas of the lung than in adjacent normal tissue [38] . In the current study we aim to identify the key cellular protein(s) involved in the inhibition cell migratory induced by a metastasis suppressor gene, OGR1.
Results

OGR1 regulates expression of CSNK2A3 and NEP but not CSNK2A1
To investigate the downstream molecules involved in the OGR1 induced inhibition of cancer cells migration, OGR1 was over-expressed transiently in A549 cells for 48 hrs and transcript expression of CSNK2A1, CSNK2A3 and NEP were analysed using semi-qPCR. Initially, OGR1 over-expression in A549 was confirmed by semi-qPCR. The results showed that OGR1 strongly up-regulates transcript expression of CSNK2A3 (CK2α intronless gene, CK2αP) and NEP. However, OGR1 does not affect significantly the expression of CSNK2A1 in A549 cells (Fig.1A, B) . Further, protein expression of [4] CK2α and NEP were analysed by immunoblotting upon OGR1 over-expression in A549 cells using respective specific antibodies (Fig. 1C, D) . The over-expression of OGR1 protein was confirmed using specific antibody against OGR1. The specific antibody for CK2α recognises proteins of both CSNK2A1 and CSNK2A3 since there are only four amino acids different in the sequence of the two genes [21] . Taking together the results of transcript expression of casein kinase 2α genes (CSNK2A1 and CSNK2A3) and protein expression of CK2α, it is clearly indicated that the increased in protein of CK2α in immunoblotting may be the product of CSNK2A3 (CK2αP). The immunoblotting against NEP confirmed that OGR1 over-expression cells increases NEP expression in A549 cells (Fig. 1C) . The overall results indicate that OGR1 up-regulates expression of CSNK2A3 and NEP, but not CSNK2A1 in lung cancer cells. Our finding is the first report to demonstrate that the expression of CSNK2A3 is regulated. There is very limited report of how CK2α gene expression is regulated inspite of many reports on aberrantly expression in cancer.
CK2αP is up stream of NEP in the OGR1 signalling pathway
To investigate whether CK2αP is upstream of NEP or vice-versa in the OGR1 signalling pathway, we assessed expression of both the proteins in the presence of either specific chemical inhibitor of CK2, CX-4945 and immunoblotting against NEP or specific chemical inhibitor of NEP, thiophan and immunoblotting against CK2α after A549 cells were transiently transfected with OGR1 or empty vector (control). Interestingly, the results showed that in the presence of CX-4945, increased expression of NEP induced by OGR1 is abrogated to a similar level of control cells ( Fig. 2A, B) . However, thoiphan did not affect expression of CK2α protein in A549 cells (Fig. 2C, D) . These results indicated that CK2αP is upstream of NEP in the signalling pathway of OGR1. It is previously reported that CK2α regulates NEP activity by phosphorylating at cytoplasmic tail [49] .
Further, we have reported earlier that OGR1 inhibits PC3 cell migration via Gαi activation [5] . Therefore, to investigate whether OGR1 induced up-regulation of CSNK2A3 in A549 is dependent of activation of Gαi, we analysed the transcript expression of CSNK2A3 in the presence or absence of pertussis toxin (PTX) upon OGR1 over-expression or empty vector. We used transcript expression of CSNK2A1 as control. The result revealed that the presence of PTX abrogated the OGR1 induced upregulation of expression of CSNK2A3 (Fig. 2E, F) .
CK2αP functionally involve in OGR1 induced inhibition of lung cancer migration
We have previously demonstrated that OGR1 is a metastatic suppressor gene in vitro as well as in vivo using an orthotopic mouse metastasis model [5] . In the current study, we found that OGR1 induces increased expression of CK2αP and NEP in transcript and protein levels. Therefore, in the current study, we investigate functional roles of both CK2α and NEP in the OGR1 induced inhibition of A549 cell migration in vitro using wound healing model in the presence or absence of inhibitor of CK2α and NEP. The results showed that OGR1 inhibits migration of A549 cells. In the presence of CK2 specific inhibitor, CX-4945, the OGR1 induced inhibition of A549 cells migration was completely [5] abrogated (Fig. 3A, B) . However, thiophan decreases the OGR1 induced inhibition of A549 cell migration only by ~30%, indicating there may be other molecule(s) other than NEP through which CK2αP induces inhibition of cancer cell migration following the action of OGR1.
Involvement of Rac1 and cdc42
The known role of the small GTPase; Rac1 and cdc42 as major drivers of cell motility prompted us to assess whether Rac1 and cdc42 are involved in the OGR1 induced up-regulation of CK2αP expression which leads to inhibition of A549 cells migration. A549 cells were transiently transfected with OGR1 alone or co-transfected with cdcT17N (dominant negative of cdc42) or RacT17N (dominant negative of Rac1). Similarly, control A549 cells were also transiently transfected with empty vector alone and co-transfected with cdcT17N or RacT17N. Initially, over-expression of OGR1 in the OGR1 transfected cells was confirmed by semi-qPCR. The results showed that in the presence of cdcT17N and RacT17N, the OGR1 induced up-regulation of CK2αP in A549 cells was significantly abrogated, suggesting that both small G proteins cdc42 and Rac1 are involved in the OGR1 induced upregulation of CK2αP in A549 cells (Fig. 4A) .
Involvement of MAPK pathway
The mitogen-activated protein kinase (MAPK) signalling pathway is widely expressed in multicellular organisms, with critical roles in multiple biological processes, such as cell proliferation, death, differentiation, migration, and invasion. To understand the involvement of MAPK pathway in the OGR1 in- 
Discussion
Although, OGR1 has been reported as novel metastasis suppressor gene, the molecular mechanism is yet to be understood. In this study, we demonstrate to show that OGR1 regulates expression of a cellular enzyme which acts as a regulator of several hallmarks of cancer cell behaviour CK2α [16] [17] [18] and an important membrane enzyme, neutral endopeptidase 24.11 (NEP, neprilysin, enkephalinase, CD 10). Our finding is the first report, to the best of our knowledge, to demonstrate that the expression of CSNK2A3 (CK2αP) is regulated by a G protein coupled receptor, OGR1. Our results revealed that OGR1 up-regulates the expression CSNK2A3 transcript but not the CSNK2A1 expression. CK2 is ubiquitously expressed and, in contrast it is believed to be a constitutively active enzyme and its regulation appears to be independent of known second messengers [51] . Considering the above findings, [6] the result of immunoblotting against a specific CK2α antibody which shows up-regulation of CK2α protein expression when OGR1 is over-expressed in A549 cells indicates that the increased in CK2α protein may be the translated product of CSNK2A3 (CK2αP). Therefore, our findings suggest that the aberrantly expressed transcript and/or protein of CK2α found in various cancer cells may be due to regulated CSNK2A3 (CK2αP) expression which is potentially inducible or repressible by several master regulators of developmental pathways. The CSNK2A3 might have an advantage over the CSNK2A1 in cancer cells in which sophisticated lineage specific genes expression is necessary [21] .
However, further investigation is necessary to find out the expression of CSNK2A1 and CSNK2A3 in various cancer cells employing strategies which can distinguish expression from one another. It is important to mention that the mRNA sequence of CSNK2A3 is 99.7% homologous to the CSNK2A3 [21] . It is previously reported CK2α inhibits NEP activity by phosphorylating cytosolic domain [49] . Therefore, our results reveal another layer of fine-tuning of NEP activity by regulating its expression induced by CK2αP, the key cellular enzyme.
In our previous study, we revealed that OGR1 inhibits prostate cancer cells migration via constitutive activity of Gαi [5] . To investigate whether OGR1's up regulation of CSNK2A3 in A549 is dependent of activation of Gαi, we analysed the transcript expression of CSNK2A3 in the presence or absence of PTX upon OGR1 over-expression or empty vector. We used transcript expression of CSNK2A1 as [7] control. Our results revealed that OGR1 up-regulate expression of CSNK2A3 transcript via Gαi activation.
To find out whether CK2αP and NEP are functionally involved in the OGR1's induced inhibition of A549 cells, we assessed cell migration using would healing assay in the presence of specific casein kinase 2α inhibitor silmitasertib (CX-4945) or NEP specific inhibitor DL-Thiorphan following overexpression of OGR1 in A549 cells. The result revealed that inhibition of CK2α abrogates OGR1's induced inhibition of A549 cell migration. The finding strongly suggested OGR1 inhibits cell migration via expression of CK2αP. Our finding supports the previous report that high levels of CK2αP correlate with higher survival rates of lung adenocarcinoma and renal clear cell carcinoma [32, 33] . The result also revealed that inhibitor of NEP abrogates the OGR1's inhibition of A549 cells to some extent (30%). Our results also revealed that CK2αP is upstream of NEP and inhibition of casein kinase 2 abrogated completely (100%) the OGR1 induced inhibition of A549 cell migration whereas inhibition of NEP abrogated only 30%. Therefore, taken together our results suggest there may be other cellular molecule other than NEP to which CK2αP targets/activates following OGR1 activation.
To understand molecular mechanism of OGR1 induced up-regulation of CK2αP expression, we as- [8]
CSNK2A3 might have an advantage over the CSNK2A1 in cancer cells in which sophisticated lineage specific genes expression is necessary.
Material and Methods
Cell culture and reagents
The A549 cells (adenocarcinomic human alveolar basal epithelial cells) were procured from the NCCS, Pune, India. The cells were maintained at 37°C, 5% CO 2 in F-12K Medium (Kaighn's Modification of Ham's F-12 Medium) supplement with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All the cell culture media, serum were procured from Gibco, USA while the antibiotics (penicillin/streptomycin) were procured from the Thermo Fisher Scientific (USA). The antibodies for ERK, phospho-ERK, JNK, phospho-JNK, p38 and phospho-p38 were purchased from the Cell Signaling, USA. Antibodies for Casein kinase 2 (Santa Cruz Biotechnology), OGR1 Cat No. 72500, abcam), NEP (Cat no. sc-9149, Santacruz Biotechnology) and β -actin (Cat no. sc-47778, Santa Cruz Biotechnology) were also procured. Specific inhibitors for JNK; SP600125, for p38; SB203580 inhibitors were procured from the abcam while the specific inhibitor for ERK, FR180204, silmitasertib (CX-4945), the specific inhibitor for Casein kinase 2α and DL-Thiorphan, the specific inhibitor for NEP were also procured from the Sigma-Aldrich.
Plasmid construction and gene transfer
pcDNA3.1-OGR1 was constructed as described previously [5] . Briefly, the OGR1 coding sequence fragment (≈ 1.2 kb) was amplified and then cloned into pcDNA3.1 (puromycin) by EcoRI and HindIII digestion. The plasmid construct was transformed in DH5α competent E. coli, and selected colonies were then cultured. Plasmid DNA was purified using QuickLyse Miniprep Kit (Qiagen, USA). The construct containing OGR1 was further confirmed by sequencing using the ABI Prism 377 Automated RNA isolation, cDNA synthesis and PCR amplification to measure the expression of casein kinase alpha and neutral endopeptidase [9] Total RNAs were extracted from 8x10 5 cultured cells using RNA isolation kit (Qiagen, Germany) according to the manufacturer's instruction. The isolated RNA were analysed for its integrity, purity and yield. Using the isolated RNA as template, first-strand complementary DNA (cDNA) was synthesised using M-MuLV Reverse Transcriptase (NEB, USA). Briefly, the extracted RNA (≈ 3µg) was reverse 1hr at room temperature. The blots were detected using chemiluminescent ECL system (GE Healthcare). Blot's Images were captured using ChemDoc (BioRad, USA).
Wound healing assay
To analyse the effect of OGR1 and CK2α, A549 cell was seeded so as to obtain 70-90% confluency at the time of transfection. Cells were transfected with empty vector (pcDNA3.1) or pcDNA3.1-OGR1.
Inhibitors; silmitasertib (CX-4945) and DL-Thiorphan were treated after 5hrs of transfection. After treatment with inhibitors, cell-free area was created (scratched) in a confluent monolayer cells using [10] 10µl filter tips. Cell migration was observed under the microscope and image was taken at 0-, 12-, 24-and 48-hrs).
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51. Guerra, B., et al., CK2: a protein kinase in need of control. Pharmacol Ther, 1999. 82(2-3): p. Stastatical significance between treated and untreated was calculated using student's "t" test. Bars indicate SD, * indicates p-value > 0.04, ** indicates p-value > 0.01 and *** indicates p-value >0.001. graph. Wound area of control 0 hr was taken as 100% and means & SD. P-values were calculated comparing with the control values of the same hrs of treatment by students' "t" test. Bars indicate SD, * indicates p-value > 0.04, ** indicates p-value > 0.01 and *** indicates p-value >0.001. β -actin was used as control for equal loading;
inhibition of JNK and p38 using specific inhibitors, SP600125 and SB2203580 respectively, abrogated the up-regulate of CSNK2A3 induced by OGR1 but not by inhibition of ERK (FR180204) whereas inhibition of ERK, JNK and p38 does not significantly affect the expression of CSNK2A1 in A549. 
